Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BFRG Bullfrog AI	$1.20 -1.6%	$1.48	$1.17 ▼ $4.84	$12.10M	0.47	522,849 shs	85,070 shs
NXTC NextCure	$5.11 -0.4%	$5.34	$2.69 ▼ $19.80	$13.70M	1.25	54,167 shs	12,265 shs
ONVO Organovo		$3.94	$1.56 ▼ $21.96	$3.47M	1.13	617,505 shs	243,634 shs
TXMD TherapeuticsMD	$1.08 -2.7%	$1.14	$0.70 ▼ $2.44	$12.50M	0.42	240,290 shs	12,979 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BFRG Bullfrog AI	-3.17%	-8.27%	-18.67%	-34.05%	-52.53%
NXTC NextCure	+1.26%	-0.69%	+3.49%	-13.60%	-73.81%
ONVO Organovo	0.00%	0.00%	0.00%	0.00%	-70.18%
TXMD TherapeuticsMD	-4.30%	-4.31%	-4.31%	-23.45%	-33.13%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BFRG Bullfrog AI	1.1863 of 5 stars	0.0	3.0	0.0	0.0	3.5	2.5	0.0
NXTC NextCure	4.1358 of 5 stars	3.3	3.0	0.0	4.3	1.1	1.7	1.3
ONVO Organovo	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TXMD TherapeuticsMD	0.1514 of 5 stars	0.0	3.0	0.0	0.0	0.0	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BFRG Bullfrog AI	0.00	N/A	N/A	N/A
NXTC NextCure	2.67	Moderate Buy	$25.50	399.02% Upside
ONVO Organovo	0.00	N/A	N/A	N/A
TXMD TherapeuticsMD	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest ONVO, NXTC, TXMD, and BFRG Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/15/2025	NXTC NextCure	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Overweight ➝ Overweight	$36.00 ➝ $15.00
7/8/2025	NXTC NextCure	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
7/1/2025	NXTC NextCure	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$36.00

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BFRG Bullfrog AI	$60K	201.60	N/A	N/A	$0.22 per share	5.45
NXTC NextCure	N/A	N/A	N/A	N/A	$11.82 per share	N/A
ONVO Organovo	$122K	0.00	N/A	N/A	$0.02 per share	0.00
TXMD TherapeuticsMD	$1.76M	7.10	N/A	N/A	$2.36 per share	0.46

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BFRG Bullfrog AI	-$6.99M	-$0.76	N/A	∞	N/A	N/A	-195.35%	-162.37%	N/A
NXTC NextCure	-$55.65M	-$25.82	N/A	N/A	N/A	N/A	-106.62%	-85.20%	11/6/2025 (Estimated)
ONVO Organovo	-$14.67M	-$10.20	N/A	N/A	N/A	-10,151.64%	-346.26%	-187.53%	N/A
TXMD TherapeuticsMD	-$2.18M	N/A	0.00	∞	N/A	-17.94%	-2.01%	-1.40%	N/A

Latest ONVO, NXTC, TXMD, and BFRG Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	BFRG Bullfrog AI	N/A	-$0.15	N/A	-$0.15	N/A	$0.03 million
8/12/2025	Q2 2025	TXMD TherapeuticsMD	N/A	$0.05	N/A	$0.05	N/A	$0.95 million
8/7/2025	Q2 2025	NXTC NextCure	-$4.62	-$11.29	-$6.67	-$11.29	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BFRG Bullfrog AI	N/A	N/A	N/A	N/A	N/A
NXTC NextCure	N/A	N/A	N/A	N/A	N/A
ONVO Organovo	N/A	N/A	N/A	N/A	N/A
TXMD TherapeuticsMD	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BFRG Bullfrog AI	N/A	3.97	3.97
NXTC NextCure	N/A	3.71	3.71
ONVO Organovo	N/A	0.72	1.72
TXMD TherapeuticsMD	N/A	2.89	2.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BFRG Bullfrog AI	0.96%
NXTC NextCure	42.65%
ONVO Organovo	8.23%
TXMD TherapeuticsMD	30.74%

Insider Ownership

Company	Insider Ownership
BFRG Bullfrog AI	24.72%
NXTC NextCure	17.90%
ONVO Organovo	3.72%
TXMD TherapeuticsMD	2.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BFRG Bullfrog AI	4	10.08 million	7.59 million	Not Optionable
NXTC NextCure	90	2.68 million	2.20 million	Optionable
ONVO Organovo	20	1.70 million	14.79 million	Optionable
TXMD TherapeuticsMD	420	11.57 million	11.31 million	Optionable

ONVO, NXTC, TXMD, and BFRG Headlines

Recent News About These Companies

TherapeuticsMD Reports Q2 2025 Financial Results

August 12, 2025 | msn.com

TherapeuticsMD: Q2 Earnings Snapshot

August 12, 2025 | finance.yahoo.com

TherapeuticsMD Announces Second Quarter 2025 Financial Results

August 12, 2025 | businesswire.com

TherapeuticsMD Inc. stock underperforms Wednesday when compared to competitors despite daily gains

July 16, 2025 | marketwatch.com

Marlan D. Walker - TXMD | TherapeuticsMD Inc. - Wall Street Journal

June 29, 2025 | wsj.com

Mayne Pharma Files Legal Complaint Against TherapeuticsMD

June 1, 2025 | tipranks.com

TherapeuticsMD Announces First Quarter 2025 Financial Results

May 13, 2025 | businesswire.com

TherapeuticsMD Inc. stock rises Monday, still underperforms market

May 12, 2025 | marketwatch.com

TherapeuticsMD Inc. stock outperforms competitors despite losses on the day

April 8, 2025 | marketwatch.com

TherapeuticsMD Announces Full Year 2024 Financial Results

March 27, 2025 | businesswire.com

TherapeuticsMD, Inc. (TXMD) Latest Press Releases & Corporate News - Yahoo Finance

March 26, 2025 | finance.yahoo.com

TherapeuticsMD Inc’s Stock Drama: Could This Be a Game-Changer for TXMD Investors?

January 7, 2025 | bovnews.comB

TherapeuticsMD Inc (TXMD) Stock: A Deeper Look at Its True Potential

January 3, 2025 | bovnews.comB

TherapeuticsMD Inc. stock remains steady Friday, still outperforms market

December 27, 2024 | marketwatch.com

TherapeuticsMD Inc. stock underperforms Friday when compared to competitors despite daily gains

November 23, 2024 | marketwatch.com

TherapeuticsMD Shifts Focus with Lower Q3 Losses

November 14, 2024 | markets.businessinsider.com

TherapeuticsMD Reports Reduced Losses Amid Strategic Shift

November 14, 2024 | markets.businessinsider.com

TherapeuticsMD Announces Third Quarter 2024 Financial Results

November 13, 2024 | finance.yahoo.com

TherapeuticsMD Inc. stock remains steady Monday, underperforms market

November 12, 2024 | marketwatch.com

TherapeuticsMD (NASDAQ:TXMD) Stock, Option Chain

November 6, 2024 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONVO, NXTC, TXMD, and BFRG Company Descriptions

Bullfrog AI NASDAQ:BFRG

$1.20 -0.02 (-1.64%)

Closing price 04:00 PM Eastern

Extended Trading

$1.20 0.00 (-0.42%)

As of 06:52 PM Eastern

Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.

NextCure NASDAQ:NXTC

$5.11 -0.02 (-0.39%)

Closing price 04:00 PM Eastern

Extended Trading

$5.09 -0.02 (-0.39%)

As of 04:04 PM Eastern

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.

Organovo NASDAQ:ONVO

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California.

TherapeuticsMD NASDAQ:TXMD

$1.08 -0.03 (-2.70%)

Closing price 03:55 PM Eastern

Extended Trading

$1.08 -0.01 (-0.46%)

As of 06:26 PM Eastern

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time